Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ: MCRB )

0.6898 +0.0514 (+8.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Earnings Scheduled For March 13, 2025
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
What's Next: Seres Therapeutics's Earnings Preview
Via Benzinga
Seres Therapeutics's Earnings: A Preview
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
Via Benzinga
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally. 
Via InvestorPlace
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.